RecruitingPhase 2NCT07223697

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

An Extension Study To Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients With Atopic Dermatitis Who Participated in Previous Afimkibart Clinical Trials

Sponsor

Hoffmann-La Roche

Enrollment

120 participants

Start Date

Jan 8, 2026

Study Type

INTERVENTIONAL

Conditions

Atopic Dermatitis

Summary

This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic Dermatitis (AD) who participated in previous afimkibart clinical trials.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Afimkibart for people with atopic dermatitis. The study is currently recruiting participants at 14 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAfimkibart

Afimkibart SC injection will be administered as per the schedule defined in the protocol.

Locations(29)

UCLA Division of Dermatology

Los Angeles, California, United States

Dermatology Research Associate

Los Angeles, California, United States

Olympian Clinical Research

Tampa, Florida, United States

Hamilton Research, LLC

Alpharetta, Georgia, United States

Revival Research Institute, LLC

Troy, Michigan, United States

Best Skin Research LLC

Camp Hill, Pennsylvania, United States

Centro de Estudos em Terapias Inovadoras ? CETI

Curitiba, Paraná, Brazil

Irmandade Da Santa Casa de Misericordia de Porto Alegre

Porto Alegre, Rio Grande do Sul, Brazil

Hospital de Clnicas de Porto Alegre

Porto Alegre, Rio Grande do Sul, Brazil

UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu

Botucatu, São Paulo, Brazil

Centro de Pesquisa São Lucas

Campinas, São Paulo, Brazil

HMCG - Hospital e Maternidade Dr. Christovo da Gama

Santo Andr, São Paulo, Brazil

Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS

Sao Jose Rio Preto, São Paulo, Brazil

Instituto Brasil de Pesquisa Clínica-IBPCLIN S/A

Rio de Janeiro, Brazil

DermEffects

London, Ontario, Canada

Lynderm Research Inc

Markham, Ontario, Canada

DermEdge

Mississauga, Ontario, Canada

Ryan Clinical Research Inc

Newmarket, Ontario, Canada

Fachklinik Bad Bentheim

Bad Bentheim, Lower Saxony, Germany

Dermatologikum Hamburg Gemeinschaftspraxis GbR

Hamburg, Germany

Azienda Ospedaliero Universitaria delle Marche

Ancona, The Marches, Italy

Centrum Medyczne Pratia Katowice I

Katowice, Silesian Voivodeship, Poland

Centrum Medyczne Pratia Gdynia

Gdynia, Poland

Specjalistyczny Gabinet Dermatologiczny dr n. med. Pawel Brzewski

Krakow, Poland

Centrum Nowoczesnych Terapii "Dobry Lekarz"

Krakow, Poland

Uniwersytecki Szpital Kliniczny im.Fryderyka Chopina w Rzeszowie

Rzeszów, Poland

Klinika Ambroziak Dermatologia

Warsaw, Poland

Clinica Universidad de Navarra

Pamplona, Navarre, Spain

Hospital Universitario Reina Sofia

Córdoba, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07223697

Related Trials

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

NCT072629831 location

Phase 1 Study of QX-4533 in Healthy Volunteers and Patients With Moderate-to-Severe Atopic Dermatitis

NCT07800104